Watson Pulls Prochieve From Guidance, But Pushes For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a disappointing advisory committee review for its progesterone gel for preterm birth, Watson said it will continue to push for approval. The company also bolsters its Australian generics business with the acquisition of Ascent.